Ana Kang
Physician Assistant · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Ana Kang’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C51767 · Cancelled
Licence status: Cancelled · since 2004 · Johns Hopkins University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$41,161
Medicare paid this office $41,161 for 366 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 91 | $9,699 | $107 |
| Return visit (30+ min) | 108 | $9,074 | $83 |
| New patient visit (30+ min) | 67 | $5,025 | $75 |
| Short return visit (20+ min) | 69 | $4,536 | $64 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 23 | $3,215 | $140 |
See all 13 services
| New patient visit (45+ min) | 91 | $9,699 | $107 |
| Return visit (30+ min) | 108 | $9,074 | $83 |
| New patient visit (30+ min) | 67 | $5,025 | $75 |
| Short return visit (20+ min) | 69 | $4,536 | $64 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 23 | $3,215 | $140 |
| Long return visit (40+ min) | 18 | $2,495 | $139 |
| New patient visit (60+ min) | 11 | $1,770 | $161 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 11 | $553 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 21 | $340 | $16 |
| Insertion of needle into vein for collection of blood sample | 34 | $294 | $9 |
| Injection of drug or substance under skin or into muscle | 22 | $268 | $12 |
| Urinalysis, manual test | 23 | $78 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $19 | None |
Who their Medicare patients are
366 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 15% · Women 57% · Also on Medicaid 10% · Health risk score 0.94. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 66% · Diabetes 23% · Coronary heart disease 22% · Chronic kidney disease 20% · Atrial fibrillation 18% · Cancer 13% · Depression 11% · Heart failure 10% · COPD 7% · Dementia 6% · Stroke 6%.
The office billed $187,293, Medicare allowed $59,740 and paid $41,161; for 684 services of 51 kinds; $135 of it was for drugs given in the office and $41,025 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 366 | 684 | 77 | 0.94 | $187,293 | $41,161 |
| 2023 | 388 | 699 | 77 | 0.91 | $181,714 | $42,730 |
| 2022 | 365 | 665 | 76 | 1.06 | $154,380 | $38,359 |
| 2021 | 321 | 590 | 77 | 1.03 | $133,434 | $36,048 |
| 2020 | 172 | 595 | 77 | 1.25 | $67,896 | $14,200 |
| 2019 | 197 | 400 | 77 | 1.07 | $71,569 | $14,997 |
| 2018 | 203 | 338 | 75 | 1.07 | $84,439 | $21,860 |
| 2017 | 23 | 23 | 68 | 1.36 | $7,726 | $1,788 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 112 | $11,064 | $98 |
| New patient visit (45+ min) | 94 | $10,060 | $107 |
| Short return visit (20+ min) | 93 | $6,026 | $63 |
| New patient visit (30+ min) | 65 | $4,779 | $74 |
| Long return visit (40+ min) | 16 | $2,078 | $130 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 14 | $1,957 | $140 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 19 | $955 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 21 | $340 | $16 |
| Injection of drug or substance under skin or into muscle | 19 | $196 | $9 |
| Insertion of needle into vein for collection of blood sample | 23 | $193 | $8 |
| Urinalysis, manual test | 24 | $89 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $18 | None |
2022: 14 services
| Return visit (30+ min) | 117 | $10,855 | $92 |
| Short return visit (20+ min) | 123 | $8,563 | $67 |
| New patient visit (45+ min) | 52 | $5,906 | $114 |
| New patient visit (30+ min) | 53 | $4,458 | $84 |
| Long return visit (40+ min) | 15 | $1,979 | $132 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 28 | $1,422 | $51 |
| Diphtheria and tetanus vaccine (7 years or older) | 15 | $334 | $22 |
| Injection of drug or substance under skin or into muscle | 29 | $332 | $11 |
| Administration of vaccine | 15 | $219 | $15 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 11 | $180 | $16 |
| Insertion of needle into vein for collection of blood sample | 32 | $95 | $3 |
| Urinalysis, manual test | 25 | $90 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $23 | None |
| Injection, ketorolac tromethamine, per 15 mg | 11 | $8 | None |
2021: 10 services
| Return visit (30+ min) | 141 | $13,527 | $95 |
| Short return visit (20+ min) | 92 | $6,905 | $69 |
| Long return visit (40+ min) | 27 | $3,814 | $141 |
| New patient visit (45+ min) | 27 | $3,047 | $113 |
| New patient visit (30+ min) | 34 | $2,654 | $78 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 47 | $2,412 | $51 |
| Injection of drug or substance under skin or into muscle | 20 | $293 | $12 |
| Urinalysis, manual test | 13 | $45 | $3 |
| Infusion, normal saline solution , 1000 cc | 14 | $36 | None |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $27 | None |
2020: 2 services
| Return visit (30+ min) | 98 | $7,242 | $72 |
| Short return visit (20+ min) | 55 | $2,732 | $49 |
2019: 7 services
| Return visit (30+ min) | 107 | $7,512 | $70 |
| Short return visit (20+ min) | 73 | $3,911 | $53 |
| Injection of drug or substance under skin or into muscle | 19 | $293 | $13 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 13 | $211 | $16 |
| Urinalysis, manual test | 15 | $51 | $3 |
| Insertion of needle into vein for collection of blood sample | 13 | $38 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $22 | None |
2018: 7 services
| Return visit (30+ min) | 86 | $7,087 | $81 |
| Short return visit (20+ min) | 92 | $4,705 | $49 |
| Short return visit | 13 | $580 | $36 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $454 | $41 |
| Injection of drug or substance under skin or into muscle | 15 | $245 | $16 |
| Urinalysis, manual test | 16 | $55 | $3 |
| Infusion, normal saline solution , 1000 cc | 11 | $24 | None |
2017: 1 service
| Emergency department visit with low level of medical decision making | 11 | $514 | $47 |
Drugs they prescribed that Part D paid
$8,598
Pharmacies billed $8,598 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
267 generic and fewer than 11 brand-name prescriptions · $8,598 in drug cost · 158 antibiotic prescriptions to 142 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Paxlovid | 11 | $2,858 | $260 |
| Albuterol Sulfate Hfa | 15 | $335 | $22 |
| Amoxicillin-Clavulanate Potass | 33 | $201 | $6 |
| Cephalexin | 40 | $180 | $4 |
| Cefuroxime | 12 | $114 | $10 |
See all 9 drugs
| Paxlovid | 11 | $2,858 | $260 |
| Albuterol Sulfate Hfa | 15 | $335 | $22 |
| Amoxicillin-Clavulanate Potass | 33 | $201 | $6 |
| Cephalexin | 40 | $180 | $4 |
| Cefuroxime | 12 | $114 | $10 |
| Doxycycline Monohydrate | 14 | $108 | $8 |
| Azithromycin | 19 | $76 | $4 |
| Ciprofloxacin | 16 | $49 | $3 |
| Naproxen | 14 | $27 | $2 |
Year by year
| 2024 | 308 | 232 | None | None | $8,598 |
| 2023 | 342 | 265 | 7% (25) | 4% | $4,004 |
| 2022 | 295 | 233 | 5% (14) | 5% | $5,366 |
| 2021 | 188 | 150 | None | None | $2,628 |
| 2020 | 91 | 78 | None | None | $1,082 |
| 2019 | 116 | 99 | None | 15% | $2,020 |
| 2018 | 109 | 83 | None | 17% | $2,773 |
| 2017 | 88 | 62 | 18% (16) | None | $1,063 |
| 2015 | 11 | None | 0% (0) | None | $157 |
| 2014 | 20 | 15 | None | None | $429 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Cephalexin | 49 | $391 | $8 |
| Amoxicillin-Clavulanate Potass | 31 | $334 | $11 |
| Nitrofurantoin Mono-Macro | 12 | $255 | $21 |
| Doxycycline Monohydrate | 23 | $245 | $11 |
| Paxlovid (Eua) | 18 | $183 | $10 |
| Azithromycin | 12 | $69 | $6 |
| Naproxen | 13 | $45 | $3 |
| Hydrocodone-Acetaminophen | 12 | $45 | $4 |
| Prednisone | 11 | $32 | $3 |
2022: 6 drugs
| Amoxicillin-Clavulanate Potass | 32 | $389 | $12 |
| Cephalexin | 40 | $306 | $8 |
| Doxycycline Monohydrate | 18 | $219 | $12 |
| Paxlovid (Eua) | 11 | $120 | $11 |
| Naproxen | 17 | $54 | $3 |
| Ciprofloxacin | 14 | $54 | $4 |
2021: 4 drugs
| Cephalexin | 27 | $158 | $6 |
| Amoxicillin-Clavulanate Potass | 13 | $124 | $10 |
| Doxycycline Monohydrate | 11 | $106 | $10 |
| Naproxen | 15 | $38 | $3 |
2020: 2 drugs
| Amoxicillin-Clavulanate Potass | 11 | $148 | $13 |
| Cephalexin | 15 | $85 | $6 |
2019: 1 drug
| Cephalexin | 14 | $130 | $9 |
2018: 1 drug
| Cephalexin | 14 | $132 | $9 |
2017: 1 drug
| Ibuprofen | 19 | $67 | $4 |
Money from drug and device companies
$248 in 2024
| 2024 | 2 | 2 | None | $248 |
| 2021 | 1 | 2 | None | $19 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Mavyret | $125 | 1 payment
|
| GlaxoSmithKline | Arexvy | $123 | 1 payment
|
See all 2 published payments
| GlaxoSmithKline | Meals · 2024-09-10 | Arexvy | $123 |
| Abbvie | Meals · 2024-08-29 | Mavyret | $125 |
See earlier years (2021)
2021: $19
| Genentech USA | Xofluza | $19 | 2 payments
|
Professional record
- NPI
- 1588063424
- Licence
- CA 51767, NY 017893California C51767: Cancelled
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2014-08-16
- NPI last updated
- 2018-01-04
This is when the NPI record was last certified, not a medical board exam.